Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International

(

VRX

) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.3%. By the end of trading, Valeant Pharmaceuticals International fell $1.88 (-1.5%) to $127.19 on heavy volume. Throughout the day, 2,624,034 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,726,600 shares. The stock ranged in price between $124.67-$129.06 after having opened the day at $128.88 as compared to the previous trading day's close of $129.07. Other companies within the Health Care sector that declined today were:

Advaxis Incorporated

(

ADXS

), down 24.8%,

Spherix

(

SPEX

), down 23.4%,

Mazor Robotics

(

MZOR

), down 11.6% and

Dehaier Medical Systems

(

DHRM

), down 10.9%.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $44.0 billion and is part of the drugs industry. Shares are up 9.9% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity.

On the positive front,

Northwest Biotherapeutics

(

NWBO

), up 15.1%,

Orthofix International N.V

(

OFIX

), up 14.5%,

Genvec

(

GNVC

), up 13.7% and

Inovio Pharmaceuticals

(

INO

), up 12.7% , were all gainers within the health care sector with

Regeneron Pharmaceuticals

(

REGN

) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.